Biocept, Inc. (Nasdaq: BIOC) 77.2% HIGHER; announced that its blood-based diagnostic, OncoCEE-BR™, was used to determine hormonal status of metastatic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE